Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131551) titled 'Furmonertinib Dose-Escalation Plus Bevacizumab with VP Shunt and Intrathecal Pemetrexed in EGFR-Mutant NSCLC with Leptomeningeal Metastases: A Phase II Study' on Sept. 3.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shanghai Pulmonary Hospital
Condition:
patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastases
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-10-01
Target Sample Size: Treatment group receiving dose-escalated furmonertinib combined with bevacizumab, ventriculoperitoneal shunt and intrathecal pemetrexed:27...